Article

Allergan customers praise rejection of Valeant proposal

Allergan has received a strong outpour of support from its physician customers, their nurses, and office staff members, as well as from patient advocacy groups and medical associations following the company’s rejection of Valeant Pharmaceuticals International’s unsolicited acquisition proposal.

 

Irvine, CA and Laval, Quebec-Allergan has received a strong outpour of support from its physician customers, their nurses, and office staff members, as well as from patient advocacy groups and medical associations following the company’s rejection of Valeant Pharmaceuticals International’s unsolicited acquisition proposal.

More than 500 letters of support were sent to Allergan to express gratitude following the rejection, the company said in a prepared statement.

“Allergan is extremely grateful for the hundreds of letters of support we have received from our customers during the past few weeks,” said David E.I. Pyott, chairman of Allergan’s board and its chief executive officer. “All of us . . . are touched that our customers have taken the time to write to tell us that our work has mattered to them and their patients, and to publicly share their support and encouragement for our company’s business model and our promising future.”

 

The company’s board unanimously rejected the Valeant offer earlier this month, as it had said the proposal “substantially undervalues Allergan, creates significant risks and uncertainties for the stockholders of Allergan based on, among other things, the unsustainability of Valeant’s acquisition-based strategy, and is not in the best interest of the company and its stockholders.”

However, Valeant is not backing down, as the company announced it will host an in-person meeting for both companies’ shareholders, scheduled for Wednesday at 8 a.m. ET in New York.

In its own prepared statement, Valeant said the meeting is in response to assertions Allergan has made that the company’s model is not sustainable, that the Bausch + Lomb portfolio is not growing, that Valeant slashes research and development, and is not committed to innovation, as well as that it will be impossible to capture $2.7 billion of synergies without impacting top-line growth.

“We continue to believe that a Valeant and Allergan merger will be a powerful combination for all stakeholders, including patients, physicians and health-care providers, employees, and shareholders,” the company said.

 

During the meeting, Valeant said it intends to announce an improved bid for Allergan shareholders to consider.

 

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.